Ron Bentsur, Chairman & CEO, 10% Owner at Nuvectis Pharma, Inc. (NVCT), bought 330 shares at $17.28 ($6K) on 2023-05-31, disclosed to the SEC on 2023-06-01.
Open-market purchase of $6k NVCT by Chairman & CEO, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade C.
Nothing distinguishes this filing.
| Filing → |
| NVCT | BUY | 2024-12-26 | $21K | — | Filing → |
| NVCT | BUY | 2024-11-18 | $98K | — | Filing → |
| NVCT | BUY | 2024-05-15 | $13K | — | Filing → |